New diabetes shot aims to rival semaglutide in blood sugar control

NCT ID NCT07653477

Not yet recruiting Disease control Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 study compares an experimental weekly injection called UBT251 to the approved drug semaglutide in adults with type 2 diabetes whose blood sugar is not well controlled by oral medications like metformin. The main goal is to see if UBT251 is at least as effective as semaglutide at lowering HbA1c over 36 weeks. The trial also tracks weight changes and safety. About 956 participants will receive one of three doses of UBT251 or semaglutide for up to 58 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: UBT251 injection
What this could lead to: If successful, UBT251 could offer a new weekly injection option for type 2 diabetes that is as effective as semaglutide for lowering blood sugar and may also help with weight loss.
What could go wrong: This is a phase 3 trial, but UBT251 is still experimental. It may not prove as effective or safe as semaglutide, and side effects (like gastrointestinal issues) are possible. Results may not apply to all diabetes patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

More trials for these conditions

Other studies related to the condition(s) this trial covers.